Business Context and Reporting Period
Company: TECHNE Corporation (BIO-TECHNE Corp)
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended June 30, 2010
Business Overview: The Company develops, manufactures, and sells biotechnology products (cytokines, antibodies, assay kits) and hematology calibrators and controls. Operations are conducted through three reportable segments: Biotechnology (R&D Systems, BiosPacific, R&D China), R&D Europe (distribution in Europe), and Hematology. The Company is a leading supplier of cytokine-related reagents to the research community and a major supplier of hematology controls.
Key Financial Metrics
| Metric | Fiscal 2010 | Fiscal 2009 | Fiscal 2008 |
|---|---|---|---|
| Net Sales | $269.0 million | $264.0 million | $257.4 million |
| Gross Margin | 79.8% | 79.0% | 79.5% |
| Operating Income | $156.3 million | $150.8 million | $144.3 million |
| Net Earnings | $109.8 million | $105.2 million | $103.6 million |
| Diluted EPS | $2.94 | $2.78 | $2.64 |
| Cash Flow from Operations | $111.3 million | $111.3 million | $115.3 million |
| Cash & Investments | $310.0 million | $265.0 million | $206.3 million |
| Long-Term Debt | $0 | $0 | $0 |
| Current Ratio | 11.8 | 16.5 | 12.8 |
Material Changes vs. Prior Period
- Revenue Growth: Consolidated net sales increased 1.9% to $269.0 million. Excluding foreign currency effects, sales increased 1.6%. The Biotechnology segment grew 2.3%, while the Hematology segment grew 5.1%. R&D Europe sales were flat (0.3% increase).
- Profitability: Net earnings increased 4.3% to $109.8 million. Gross margins improved to 79.8% due to incremental profit on increased sales volume in the Biotechnology segment.
- Tax Benefit: Net earnings included a $4.7 million tax benefit resulting from a foreign currency exchange loss on the repatriation of $74.4 million in earnings from R&D Europe to the U.S. Excluding this benefit, the effective tax rate would have been 32.8%.
- Expense Management: Selling, general, and administrative (SG&A) expenses decreased 3.0% to $32.2 million, driven by lower legal fees and profit-sharing expenses. Research and development (R&D) expenses increased 6.6% to $25.1 million due to the development of over 1,400 new biotechnology products.
- Capital Allocation: The Company repurchased and retired 284,000 shares of common stock for $16.9 million and paid cash dividends totaling $38.4 million.
Guidance, Outlook, and Risks
- Outlook: Management expects income tax rates for fiscal 2011 to range from 32% to 33%, excluding retroactive R&D tax credits. Capital additions for fiscal 2011 are expected to be approximately $3.6 million, financed by available cash.
- Product Pipeline: The Company plans to release new cytokines, antibodies, and assay kits in the coming year. All new products are for research purposes and do not require FDA clearance.
- Key Risks:
- Research Spending: Revenues are significantly dependent on spending by pharmaceutical, biotechnology, and academic research institutions.
- Foreign Exchange: Approximately 29% of sales are in foreign currencies (Euro, British Pound, Chinese Yuan), exposing the Company to exchange rate fluctuations.
- Competition: Intense competition exists in both biotechnology and hematology markets from major firms like GE Healthcare, BD Biosciences, and Beckman Coulter.
- Intellectual Property: The Company relies on patents and licenses; potential infringement litigation or failure to secure new patents could impact operations.
- Investments: The Company holds equity investments in development-stage companies (e.g., ChemoCentryx, Hemerus, Nephromics) which carry risks of impairment if funding or regulatory approvals are not secured.
- Legal Proceedings: The Company won a patent interference judgment against Streck, Inc., finding R&D Systems was the first to invent integrated hematology controls containing reticulocytes. The Company does not believe the resolution will materially impact financial statements.
Investor Verification Checklist
- Foreign Currency Impact: Verify the sensitivity of future earnings to fluctuations in the Euro and British Pound, given 29% of sales are foreign.
- One-Time Tax Benefit: Confirm the sustainability of the effective tax rate by excluding the $4.7 million one-time benefit from the repatriation of foreign earnings.
- Investment Valuation: Review the status and fair value of equity method investments (ChemoCentryx, Hemerus, Nephromics, ACTGen) totaling approximately $20.6 million, as these are subject to impairment risks.
- Inventory Reserves: Note the $19.9 million reserve for excess protein and antibody inventory; monitor if this level increases due to product obsolescence or demand shifts.
- Customer Concentration: Confirm that no single customer accounts for more than 10% of revenue, as stated in the filing.